标题
PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression
作者
关键词
-
出版物
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 18, Issue 6, Pages 1331
出版商
MDPI AG
发表日期
2017-06-22
DOI
10.3390/ijms18061331
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Identification of a subset of human natural killer cells expressing high levels of programmed death 1: A phenotypic and functional characterization
- (2017) Silvia Pesce et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy
- (2017) Jan Willem Kleinovink et al. OncoImmunology
- Absence of PD-L1 on tumor cells is associated with reduced MHC I expression and PD-L1 expression increases in recurrent serous ovarian cancer
- (2017) Stefanie Aust et al. Scientific Reports
- Blockade of programmed death-1/programmed death ligand pathway enhances the antitumor immunity of human invariant natural killer T cells
- (2016) Toshiko Kamata et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Rejection versus escape: the tumor MHC dilemma
- (2016) Federico Garrido et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy
- (2016) Xiaohong Wang et al. CANCER RESEARCH
- Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
- (2016) Jianjun Gao et al. CELL
- Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
- (2016) Willy Hugo et al. CELL
- Dual Faces of IFN in Cancer Progression: A Role of PD-L1 Induction in the Determination of Pro- and Antitumor Immunity
- (2016) M. Mandai et al. CLINICAL CANCER RESEARCH
- HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma
- (2016) Hong Zheng et al. CLINICAL CANCER RESEARCH
- The urgent need to recover MHC class I in cancers for effective immunotherapy
- (2016) Federico Garrido et al. CURRENT OPINION IN IMMUNOLOGY
- Basics of PD-1 in self-tolerance, infection, and cancer immunity
- (2016) Shunsuke Chikuma International Journal of Clinical Oncology
- Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
- (2016) Antoni Ribas et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy
- (2016) Weijie Ma et al. Journal of Hematology & Oncology
- PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma
- (2016) Xi-wen Bi et al. Journal of Hematology & Oncology
- Predictive biomarkers for checkpoint inhibitor-based immunotherapy
- (2016) Geoffrey T Gibney et al. LANCET ONCOLOGY
- Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers
- (2016) Keisuke Kataoka et al. NATURE
- Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses
- (2016) Kelly D Moynihan et al. NATURE MEDICINE
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
- (2016) Jesse M. Zaretsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- MYC regulates the antitumor immune response through CD47 and PD-L1
- (2016) S. C. Casey et al. SCIENCE
- Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity
- (2016) R. D. Dorand et al. SCIENCE
- Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
- (2016) N. McGranahan et al. SCIENCE
- CD4+ T cell-mediated cytotoxicity eliminates primary tumor cells in metastatic melanoma through high MHC class II expression and can be enhanced by inhibitory receptor blockade
- (2016) Hongxia Yan et al. TUMOR BIOLOGY
- PD-L1 expression in human cancers and its association with clinical outcomes
- (2016) Jinming Yu et al. OncoTargets and Therapy
- Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy
- (2016) Douglas B. Johnson et al. Nature Communications
- Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade
- (2016) P.-L. Chen et al. Cancer Discovery
- Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
- (2016) Daniel Sanghoon Shin et al. Cancer Discovery
- PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma
- (2016) Asma Beldi-Ferchiou et al. Oncotarget
- Classical Hodgkin Lymphoma with Reduced 2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status
- (2016) M. G. M. Roemer et al. Cancer Immunology Research
- Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells
- (2016) B. Homet Moreno et al. Cancer Immunology Research
- Intratumoral expression levels of PD-L1, GZMA, and HLA-A along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma
- (2016) Hiroyuki Inoue et al. OncoImmunology
- Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy
- (2016) Maarten Swart et al. Frontiers in Oncology
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
- (2015) Suzanne L. Topalian et al. CANCER CELL
- Control of PD-L1 Expression by Oncogenic Activation of the AKT–mTOR Pathway in Non–Small Cell Lung Cancer
- (2015) Kristin J. Lastwika et al. CANCER RESEARCH
- Classifying Cancers Based on T-cell Infiltration and PD-L1
- (2015) Michele W.L. Teng et al. CANCER RESEARCH
- From mice to humans: developments in cancer immunoediting
- (2015) Michele W.L. Teng et al. JOURNAL OF CLINICAL INVESTIGATION
- Combination cancer immunotherapies tailored to the tumour microenvironment
- (2015) Mark J. Smyth et al. Nature Reviews Clinical Oncology
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Vaccine-induced tumor regression requires a dynamic cooperation between T cells and myeloid cells at the tumor site
- (2015) Maxime Thoreau et al. Oncotarget
- HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade
- (2015) D. M. Woods et al. Cancer Immunology Research
- Immunomodulatory effect of peritumorally administered interferon-beta on melanoma through tumor-associated macrophages
- (2015) Aya Kakizaki et al. OncoImmunology
- Innate vs. Adaptive: PD-L1-mediated immune resistance by melanoma
- (2015) Sneha Berry et al. OncoImmunology
- Cutting Edge: Programmed Death-1/Programmed Death Ligand 1 Interaction Regulates the Induction and Maintenance of Invariant NKT Cell Anergy
- (2014) W.-S. Chang et al. JOURNAL OF IMMUNOLOGY
- Comprehensive molecular characterization of gastric adenocarcinoma
- (2014) Adam J. Bass et al. NATURE
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Programmed Death 1 Deficiency Induces the Polarization of Macrophages/Microglia to the M1 Phenotype After Spinal Cord Injury in Mice
- (2014) Anhui Yao et al. Neurotherapeutics
- Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells
- (2014) K. Kim et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints
- (2014) Nicolas J. Llosa et al. Cancer Discovery
- Exomics and immunogenics
- (2014) Stéphane Champiat et al. OncoImmunology
- At the Bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy
- (2013) Andrew M. Intlekofer et al. JOURNAL OF LEUKOCYTE BIOLOGY
- MHC Class I Antigen Processing and Presenting Machinery: Organization, Function, and Defects in Tumor Cells
- (2013) P. Leone et al. JNCI-Journal of the National Cancer Institute
- The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment
- (2013) Paolo A Ascierto et al. Journal of Translational Medicine
- Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
- (2013) E. A. Akbay et al. Cancer Discovery
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
- (2012) J. M. Taube et al. Science Translational Medicine
- Revisiting the role of T cells in tumor regression
- (2012) Nadège Bercovici et al. OncoImmunology
- Targeting NKT cells and PD-L1 pathway results in augmented anti-tumor responses in a melanoma model
- (2011) Kevin Durgan et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- The Two Faces of Interferon- in Cancer
- (2011) M. R. Zaidi et al. CLINICAL CANCER RESEARCH
- Tumor-reactive CD4+T cells: plasticity beyond helper and regulatory activities
- (2011) Sergio A Quezada et al. Immunotherapy
- IFN- Directly Promotes Programmed Cell Death-1 Transcription and Limits the Duration of T Cell-Mediated Immunity
- (2011) S. Terawaki et al. JOURNAL OF IMMUNOLOGY
- MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers
- (2011) Christian Steidl et al. NATURE
- Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma
- (2010) M. R. Green et al. BLOOD
- Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-associated macrophages
- (2010) Ilia N. Buhtoiarov et al. IMMUNOLOGY
- PD-1 negatively regulates interleukin-12 expression by limiting STAT-1 phosphorylation in monocytes/macrophages duringchronic hepatitis C virus infection
- (2010) Cheng J. Ma et al. IMMUNOLOGY
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- (2010) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
- (2009) M. Ahmadzadeh et al. BLOOD
- In Situ Cytotoxic and Memory T Cells Predict Outcome in Patients With Early-Stage Colorectal Cancer
- (2009) Franck Pagès et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-1-Mediated Suppression of IL-2 Production Induces CD8+ T Cell Anergy In Vivo
- (2009) S. Chikuma et al. JOURNAL OF IMMUNOLOGY
- PD-1/PD-L Blockade Prevents Anergy Induction and Enhances the Anti-Tumor Activities of Glycolipid-Activated Invariant NKT Cells
- (2009) V. V. Parekh et al. JOURNAL OF IMMUNOLOGY
- Cytotoxic human CD4+ T cells
- (2008) Pablo J van de Berg et al. CURRENT OPINION IN IMMUNOLOGY
- Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy
- (2008) Rafael Carretero et al. IMMUNOGENETICS
- Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)
- (2008) M. Marzec et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now